On August 17, 2017, the FDA approved inotuzumab ozogamicin (Besponsa), a targeted therapy, for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The drug blocks cancer growth by binding to B-cell ALL cells that express CD22. The FDA designated inotuzu_mab ozogamicin as an orphan drug and applied its priority review for this approval.
Keep up to date with the latest news from us via social networks:
To sign up for our print publication or e-newsletter, please enter your contact information below.
